skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8799

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma

Review

(2070) Views  (566) Full article downloads

Authors: Bukowski RM

Published Date August 2011 Volume 2011:3 Pages 273 - 285
DOI: http://dx.doi.org/10.2147/CMAR.S15557

Ronald M Bukowski
Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA

Abstract: The management of renal cell carcinoma (RCC) has undergone significant changes during the past 10 years, with the treatment of metastatic RCC undergoing the most radical changes. These developments reflect an enhanced understanding of this tumor's underlying biology, which was then translated into the development of a new treatment paradigm. Current therapeutic approaches for the management of patients with metastatic RCC utilize knowledge of histology, molecular abnormalities, clinical prognostic factors, the natural history of this malignancy, and the treatment efficacy and toxicity of available agents. The treatment options available for patients with metastatic RCC have changed dramatically over the past 6 years. Interferon-α and interleukin-2 were the previous mainstays of therapy, but since December 2005, six new agents have been approved in the US for the treatment of advanced RCC. Three are multi-targeted tyrosine kinase inhibitors (TKI) including sunitinib, sorafenib, and pazopanib, two target the mammalian target of rapamycin (temsirolimus and everolimus), and one is a humanized monoclonal antibody (bevacizumab in combination with interferon-α). The current review focuses on the newest TKI available to treat patients with metastatic RCC, pazopanib. The development of this agent both preclinically and clinically is reviewed. The efficacy and safety data from the pivotal clinical trials are discussed, and the potential role of pazopanib in the treatment of patients with metastatic RCC in comparison to other treatment alternatives is critically appraised. This agent has a favorable overall risk benefit, and the available data demonstrate efficacy in patients with metastatic RCC who are either treatment-naïve or cytokine refractory. It therefore represents another alternative for treatment of metastatic RCC patients.

Keywords: renal cell carcinoma, metastatic, pazopanib







Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
Cardiovascular risk during hormonal treatment in patients with prostate cancer
Deciding what information is necessary: do patients with advanced cancer want to know all the details?
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
Potential clinical applications of halichondrins in breast cancer and other neoplasms
Management of cutaneous T cell lymphoma: new and emerging targets and treatment options
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University